Compare Medpace Holdings Inc (MEDP) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Annaly Capital Management, Inc. — how do they compare? Medpace Holdings Inc trades at $614.07 (market cap $16.82B), while Annaly Capital Management, Inc. trades at $18.28 (market cap $13.77B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Annaly Capital Management, Inc. pays a 16.42% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Annaly Capital Management, Inc. for 91 Days on average.
| MEDP | NLY | |
|---|---|---|
Market Cap | $16.82B | $13.77B |
Volume | 223,093 | 21,283,879 |
Sector | Health | Real Estate |
52-Week High | $630.19 | $24.40 |
52-Week Low | $393.42 | $17.93 |
Typical Hold Time | 14 Days | 91 Days |
Enterprise Value | $16.44B | $135.80B |
Dividend Yield | — | 16.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
NLY trades at $18.07, up 0.78% today, with a bearish technical signal despite oversold RSI readings. The stock offers a high dividend yield near 15% and trades below book value (P/B 0.91). Recent quarters show consistent EPS beats, with Q3 2026 results pending. The company's portfolio expansion to $107 billion in 2026 supports earnings growth, though cash flow trends show heavy reliance on financing activities.
The outlook balances high income potential against interest rate sensitivity. Analyst consensus is bullish with a $22 price target, but rising debt-to-asset ratios and mortgage rate volatility pose risks. Sustainable dividend coverage remains key for total return prospects amid market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
